Available from: Gianazza, E., Brioschi, M., Fernandez, A
The control group received a single intraperitoneal injection of 30% GalN saline solution between 9:00 and 10:00 am at a dose of 1.4 g/kg body weight, and the proline group received a 10% proline solution orally at a dose of 2 g/kg body weight 1 h before GalN administration
As with any therapy, long-term studies are still limited, so ongoing observation and clinical research will further define its safety profile
It has been observed that protein expression of other subunits of cBAF is reduced in the absence of SMARCB1 21,22
While its prevalence in patients with cardiovascular diseases stands at 29.7%, those with liver cirrhosis experience a strikingly elevated rate of 48.1% (Kim et al., 2017)